Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 2/2016

01-02-2016 | Antiphospholipid Syndrome (S Zuily, Section Editor)

Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome

Authors: Cécile M. Yelnik, Elizabeth Kozora, Simone Appenzeller

Published in: Current Rheumatology Reports | Issue 2/2016

Login to get access

Abstract

Thrombotic manifestations of antiphospholipid syndrome (APS) are well known, and various non-stroke neuro-psychiatric manifestations (NPMs) have also been consistently described, but their place in APS remains unclear. Some syndromes, such as migraine or cognitive dysfunction, are frequently described in APS, whereas others, like seizure, multiple sclerosis-like symptoms, transverse myelitis, movement disorders, or psychiatric symptoms, are rarely found. Overlap with other autoimmune diseases, in particular with systemic lupus erythematosus, the lack of large sample size prospective studies, and discrepancies in antiphospholipid antibody (aPL) determinations complicate the study of the relationship between those disorders and aPL/APS. This review article aimed to summarize updated data on pathophysiologic, epidemiologic, and radiologic findings about non-stroke NPM described in primary APS and aPL-positive patients without overlap of other autoimmune diseases.
Literature
1.
Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet Lond Engl. 1983;2(8361):1211–4.CrossRef
2.
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–11.PubMedCrossRef
3.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH. 2006;4(2):295–306.PubMedCrossRef
4.
Kent M, Alvarez F, Vogt E, Fyffe R, Ng AK, Rote N. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J Rheumatol. 1997;24(9):1725–33.PubMed
5.
Caronti B, Pittoni V, Palladini G, Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci. 1998;156(2):211–9.PubMedCrossRef
6.
Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus. 2003;12(6):436–42.PubMedCrossRef
7.••
Abreu MM, Danowski A, Wahl DG, Amigo M-C, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14. Last report of international experts’ conference, which summarizes experts’ conclusions on clinical non-criteria manifestations of APS and their place in the classification criteria.PubMedCrossRef
8.
Jacobson MW, Rapport LJ, Keenan PA, Coleman RD, Tietjen GE. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol. 1999;21(2):251–64.PubMedCrossRef
9.
Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M. Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus. 2010;19(5):613–9.PubMedCrossRef
10.•
Kozora E, Erkan D, Zhang L, Zimmerman R, Ramon G, Ulug AM, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Clin Exp Rheumatol. 2014;32(1):34–40. Proof of aPL implication in cognitive dysfunction independently of overlap with lupus.PubMed
11.
Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006;166(20):2278–84.PubMedCrossRef
12.•
Coín MA, Vilar-López R, Peralta-Ramírez I, Hidalgo-Ruzzante N, Callejas-Rubio JL, Ortego-Centeno N, et al. The role of antiphospholipid autoantibodies in the cognitive deficits of patients with systemic lupus erythematosus. Lupus. 2015;24(8):875–9. Recent paper with good methodology to evaluate the association between aPL and cognitive dysfunction.PubMedCrossRef
13.
Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64(10):1490–3.
14.
Gómez-Puerta JA, Martín H, Amigo M-C, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84(4):225–30.CrossRef
15.
De Carvalho JF, Pasoto SG, Appenzeller S. Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke. Clin Dev Immunol. 2012;2012:981519.PubMedPubMedCentral
16.
Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Rovensky J, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology. 2005;210(10):749–54.
17.
Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N. Neurological manifestations in patients with antiphospholipid syndrome. Iran J Neurol. 2013;12(4):172–5.
18.
Appenzeller S, Yeh S, Maruyama M, Barros SM, de Carvalho JF. Chorea in primary antiphospholipid syndrome is associated with rheumatic fever. Rheumatol Int. 2012;32(9):2857–61.PubMedCrossRef
19.
Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.PubMedCrossRef
20.
Sherer Y, Hassin S, Shoenfeld Y, Levy Y, Livneh A, Ohry A, et al. Transverse myelitis in patients with antiphospholipid antibodies—the importance of early diagnosis and treatment. Clin Rheumatol. 2002;21(3):207–10.PubMedCrossRef
21.
Chapman J, Abu-Katash M, Inzelberg R, Yust I, Neufeld MY, Vardinon N, et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci. 2002;15(203–204):81–4.CrossRef
22.
Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc JINS. 1997;3(4):377–86.PubMed
23.
Leritz E, Brandt J, Minor M, Reis-Jensen F, Petri M. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. J Clin Exp Neuropsychol. 2002;24(4):527–33.PubMedCrossRef
24.
Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42(4):735–41.PubMedCrossRef
25.
Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, Ceccarelli F, et al. Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS ONE. 2012;7(3):e33824.PubMedPubMedCentralCrossRef
26.
Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus. 1995;4(6):482–5.PubMedCrossRef
27.
Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000;11(1):36–8.PubMedCrossRef
28.
Hughes GRV. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J. 2003;79(928):81–3.PubMedPubMedCentralCrossRef
29.
Iñiguez C, Pascual C, Pardo A, Martinez-Castrillo JC, Alvarez-Cermeño JC. Antiphospholipid antibodies in migraine. Headache. 1991;31(10):666–8.PubMedCrossRef
30.
Cavestro C, Micca G, Molinari F, Bazzan M, DI Pietrantonj C, Aloi R, et al. Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost JTH. 2011;9(7):1350–4.PubMedCrossRef
31.
Rajan R, Ahluwalia J, Lal V. Prothrombotic states in migraine. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2014;20(8):851–6.CrossRef
32.
Hering R, Couturier EG, Steiner TJ, Asherson RA, Clifford RF. Anticardiolipin antibodies in migraine. Cephalalgia Int J Headache. 1991;11(1):19–21.CrossRef
33.
Williams FMK, Cherkas LF, Bertolaccini ML, Murru V, Surdulescu GL, Hughes GRV, et al. Migraine and antiphospholipid antibodies: no association found in migraine-discordant monozygotic twins. Cephalalgia Int J Headache. 2008;28(10):1048–52.CrossRef
34.
Tsakiris DA, Kappos L, Reber G, Marbet GA, Le Floch-Rohr J, Roux E, et al. Lack of association between antiphospholipid antibodies and migraine. Thromb Haemost. 1993;69(5):415–7.PubMed
35.
Tietjen GE, Day M, Norris L, Aurora S, Halvorsen A, Schultz LR, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology. 1998;50(5):1433–40.PubMedCrossRef
36.
Intiso D, Crociani P, Fogli D, Grandone E, Cappucci G, Di Rienzo F, et al. Occurrence of factor V Leiden mutation (Arg506Gln) and anticardiolipin antibodies in migraine patients. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2002;22(6):455–8.
37.
Cuadrado MJ, Khamashta MA, Hughes GR. Migraine and stroke in young women. QJM Mon J Assoc Physicians. 2000;93(5):317–8.CrossRef
38.
Stojanovich L, Kontic M, Smiljanic D, Djokovic A, Stamenkovic B, Marisavljevic D. Association between non-thrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome. Clin Exp Rheumatol. 2013;31(5):756–60.PubMed
39.••
Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011–8. Provide strong epidemiologic data from the largest prospective cohort of APS patients.PubMedCrossRef
40.
Francès C, Niang S, Laffitte E, le Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52(6):1785–93.PubMedCrossRef
41.
Toubi E, Krause I, Fraser A, Lev S, Stojanovich L, Rovensky J, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol. 2005;23(4):499–504.PubMed
42.
Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von Landenberg P, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31(7):1344–8.PubMed
43.
Liimatainen S, Peltola M, Fallah M, Kharazmi E, Haapala A-M, Peltola J. The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. Eur J Neurol Off J Eur Fed Neurol Soc. 2009;16(1):134–41.
44.
Maalouf NN, Hinduja A, Shihabuddin BS. Primary antiphospholipid syndrome manifesting as partial status epilepticus. Neurosci Riyadh Saudi Arab. 2013;18(2):160–2.
45.•
Ong M-S, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014;71(5):569–74. First study to properly assess the link between APS diagnosis and epilepsy in a large study-population cohort.PubMedPubMedCentralCrossRef
46.
Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000;79(1):57–68.CrossRef
47.
Ahbeddou N, Ait Ben Haddou E, Hammi S, Slimani C, Regragui W, Benomar A, et al. Multiple sclerosis associated with antiphospholipid syndrome: diagnostic and therapeutic difficulties. Rev Neurol (Paris). 2012;168(1):65–9.CrossRef
48.
Lima I, Melo A, Brandi IV, Costa O, Santiago M. Lupoid sclerosis: what is the role of antiphospholipid antibodies? J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2007;13(2):85–6.
49.
Komolafe MA, Komolafe EO, Sunmonu TA, Olateju SO, Asaleye CM, Adesina OA, et al. New onset neuromyelitis optica in a young Nigerian woman with possible antiphospholipid syndrome: a case report. J Med Case Reports. 2008;2:348.PubMedCentralCrossRef
50.
Fernández-Fernández FJ, Rivera-Gallego A, de la Fuente-Aguado J, Pérez-Fernández S, Muñoz-Fernández D. Antiphospholipid syndrome mimicking multiple sclerosis in two patients. Eur J Intern Med. 2006;17(7):500–2.PubMedCrossRef
51.
Liedorp M, Sanchez E, van Hoogstraten IMW, von Blomberg BME, Barkhof F, Polman CH, et al. No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up. J Neurol Neurosurg Psychiatry. 2007;78(10):1146–8.PubMedPubMedCentralCrossRef
52.
Bidot CJ, Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn YS, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol. 2007;7:36.PubMedPubMedCentralCrossRef
53.
Vilisaar J, Wilson M, Niepel G, Blumhardt LD, Constantinescu CS. A comparative audit of anticardiolipin antibodies in oligoclonal band negative and positive multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2005;11(4):378–80.CrossRef
54.
Sastre-Garriga J, Reverter JC, Font J, Tintoré M, Espinosa G, Montalban X. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol. 2001;49(3):408–11.PubMedCrossRef
55.
Roussel V, Yi F, Jauberteau MO, Couderq C, Lacombe C, Michelet V, et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun. 2000;14(3):259–65.PubMedCrossRef
56.
IJdo JW, Conti-Kelly AM, Greco P, Abedi M, Amos M, Provenzale JM, et al. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus. 1999;8(2):109–15.PubMedCrossRef
57.
Cordoliani MA, Michon-Pasturel U, Rerat K, Arvieux J, Masy E, Hachulla E, et al. Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne. 1998;19(9):635–9.CrossRef
58.
Sugiyama Y, Yamamoto T. Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Tohoku J Exp Med. 1996;178(3):203–15.PubMedCrossRef
59.
Fukazawa T, Moriwaka F, Mukai M, Hamada T, Koike T, Tashiro K. Anticardiolipin antibodies in Japanese patients with multiple sclerosis. Acta Neurol Scand. 1993;88(3):184–9.PubMedCrossRef
60.
Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44(4):629–34.PubMedCrossRef
61.
Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F, et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol. 1998;55(4):517–21.PubMedCrossRef
62.
Heinzlef O, Weill B, Johanet C, Sazdovitch V, Caillat-Zucman S, Tournier-Lasserve E, et al. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry. 2002;72(5):647–9.PubMedPubMedCentralCrossRef
63.
Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N. Neurological manifestations in patients with antiphospholipid syndrome. Iran J Neurol. 2013;12(4):172–5.PubMedPubMedCentral
64.
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72(2):113–24.CrossRef
65.
Orzechowski NM, Wolanskyj AP, Ahlskog JE, Kumar N, Moder KG. Antiphospholipid antibody-associated chorea. J Rheumatol. 2008;35(11):2165–70.PubMedCrossRef
66.
Reiner P, Galanaud D, Leroux G, Vidailhet M, Haroche J, Huong DLT, et al. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Mov Disord Off J Mov Disord Soc. 2011;26(13):2422–7.CrossRef
67.
Huang Y-C, Lyu R-K, Chen S-T, Chu Y-C, Wu Y-R. Parkinsonism in a patient with antiphospholipid syndrome—case report and literature review. J Neurol Sci. 2008;267(1–2):166–9.PubMedCrossRef
68.
Carecchio M, Comi C, Varrasi C, Stecco A, Sainaghi PP, Bhatia K, et al. Complex movement disorders in primary antiphospholipid syndrome: a case report. J Neurol Sci. 2009;281(1–2):101–3.PubMedCrossRef
69.•
Chen W-H, Chen C-H, Chui C, Lui C-C, Chen C-J, Yin H-L. Antiphospholipid antibodies and cerebellar ataxia: a clinical analysis and literature review. Neuroimmunomodulation. 2014;21(6):283–90. Interesting recent review, up to date on cerebellar ataxia in aPL and APS patients.PubMedCrossRef
70.
Ishikawa N, Kobayashi M. Recurrent acute cerebellar ataxia associated with anti-cardiolipin antibodies. Brain Dev. 2010;32(7):588–91.PubMedCrossRef
71.
Sokol DK, O’Brien RS, Wagenknecht DR, Rao T, McIntyre JA. Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol. 2007;190(1–2):151–6.PubMedCrossRef
72.
Schwartz M, Rochas M, Weller B, Sheinkman A, Tal I, Golan D, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry. 1998;59(1):20–3.PubMedCrossRef
73.
Schwartz M, Silver H. Lymphocytes, autoantibodies and psychosis—coincidence versus etiological factor: an update. Isr J Psychiatry Relat Sci. 2000;37(1):32–6.PubMed
74.
Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun. 2006;27(2):71–80.PubMedCrossRef
75.
Chengappa KN, Carpenter AB, Keshavan MS, Yang ZW, Kelly RH, Rabin BS, et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry. 1991;30(7):731–5.PubMedCrossRef
76.
Maes M, Meltzer H, Jacobs J, Suy E, Calabrese J, Minner B, et al. Autoimmunity in depression: increased antiphospholipid autoantibodies. Acta Psychiatr Scand. 1993;87(3):160–6.PubMedCrossRef
77.
78.
Barros S, de Carvalho J. Pathological gambling and primary antiphospholipid (Hughes) syndrome: a unique neuropsychiatric association. Lupus. 2011;20(10):1086–9.PubMedCrossRef
79.
80.
Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus. 2002;11(11):736–43.PubMedCrossRef
81.
Katzav A, Shoenfeld Y, Chapman J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin Rev Allergy Immunol. 2010;38(2–3):196–200.PubMedCrossRef
82.
Appenzeller S, Lapa AT, de Carvalho JF, Peres FA, Shoenfeld Y. Cognitive dysfunction and antiphospholipid antibodies. Curr Rheumatol Rep. 2012;14(1):95–8.PubMedCrossRef
83.
Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001;10(7):496–9.PubMedCrossRef
84.•
Frauenknecht K, Katzav A, Weiss Lavi R, Sabag A, Otten S, Chapman J, et al. Mice with experimental antiphospholipid syndrome display hippocampal dysfunction and a reduction of dendritic complexity in hippocampal CA1 neurones. Neuropathol Appl Neurobiol. 2015;41(5):657–71. Interesting and recent bench paper, which provide structural basis for the behavioral and cognitive abnormalities of APS mice model.PubMedCrossRef
85.
Katzav A, Ben-Ziv T, Blank M, Pick CG, Shoenfeld Y, Chapman J. Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. J Neuroimmunol. 2014;272(1–2):10–5.PubMedCrossRef
86.
Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest. 1997;100(3):613–9.PubMedPubMedCentralCrossRef
87.
Nowacki P, Ronin-Walknowska E, Ossowicka-Stepińska J. Neuropathological changes within the brain of rabbits with experimental model of antiphospholipid syndrome in different time after immunization. Folia Neuropathol Assoc Pol Neuropathol Med Res Cent Pol Acad Sci. 1999;37(4):269–72.
88.
Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 1999;8(2):127–33.PubMedCrossRef
89.
Chapman J, Soloveichick L, Shavit S, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol. 2005;12(3):175–80.PubMedPubMedCentralCrossRef
90.
Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15(4):191–7.PubMedCrossRef
91.
Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci. 1994;54(15):1119–25.PubMedCrossRef
92.
Carter D, Olchovsky D, Yonath H, Langevitz P, Ezra D. Simultaneous deep vein thrombosis and transverse myelitis with negative serology as a first sign of antiphospholipid syndrome: a case report and review of the literature. Clin Rheumatol. 2006;25(5):756–8.PubMedCrossRef
93.
Erkan D, Kozora E, Lockshin MD. Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome. Pathophysiol Off J Int Soc Pathophysiol ISP. 2011;18(1):93–102.
94.•
Zhu D-S, Fu J, Zhang Y, Li S-X, Zhang G-X, Guan Y-T, et al. Neurological antiphospholipid syndrome: clinical, neuroimaging, and pathological characteristics. J Neurol Sci. 2014;346(1–2):138–44. Good recent review on neurologic imaging in APS.PubMedCrossRef
95.
Lampropoulos CE, Koutroumanidis M, Reynolds PPM, Manidakis I, Hughes GRV, D’Cruz DP. Electroencephalography in the assessment of neuropsychiatric manifestations in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum. 2005;52(3):841–6.PubMedCrossRef
96.
Pereira FR, Macri F, Jackowski MP, Kostis WJ, Gris J-C, Beregi J-P, et al. Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms. Eur Radiol. 2015.
97.
98.
Asherson RA, Giampaulo D, Singh S, Sulman L. Dramatic response of severe headaches to anticoagulation in a patient with antiphospholipid syndrome. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2007;13(3):173–4.
99.
Roie EV, Labarque V, Renard M, Van Geet C, Gabriëls L. Obsessive-compulsive behavior as presenting symptom of primary antiphospholipid syndrome. Psychosom Med. 2013;75(3):326–30.PubMedCrossRef
100.
Lai J-Y, Wu P-C, Chen H-C, Lee M-B. Early neuropsychiatric involvement in antiphospholipid syndrome. Gen Hosp Psychiatry. 2012;34(5):579.e1–3.PubMedCrossRef
101.
Ayalew Y, Khattak F. Antiphospholipid antibody syndrome presenting with hemichorea. Case Rep Rheumatol. 2012;2012:471543.PubMedPubMedCentral
102.
Safarpour D, Buckingham S, Jabbari B. Chorea associated with high titers of antiphospholipid antibodies in the absence of antiphospholipid antibody syndrome. Tremor Hyperkinetic Mov N Y N. 2015;5:294.
103.
Demonty J, Gonce M, Ribai P, Verellen-Dumoulin C, Hustinx R. Chorea associated with anti-phospholipid antibodies: case report. Acta Clin Belg. 2010;65(5):350–3.PubMedCrossRef
104.
Brogna C, Mariotti P, Manna R. Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus. 2014;23(14):1449–51.PubMedCrossRef
105.••
Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limón P, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73(6):1176–80. Only therapeutic trial to evaluate the benefit of an immunosuppressive drug in non-criteria APS manifestations.PubMedPubMedCentralCrossRef
Metadata
Title
Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome
Authors
Cécile M. Yelnik
Elizabeth Kozora
Simone Appenzeller
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 2/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-016-0568-x

Other articles of this Issue 2/2016

Current Rheumatology Reports 2/2016 Go to the issue

Antiphospholipid Syndrome (S Zuily, Section Editor)

Organ Damage and Quality of Life in Antiphospholipid Syndrome

Scleroderma (J Varga, Section Editor)

Cellular Therapies in Systemic Sclerosis: Recent Progress

Pediatric Rheumatology (S Ozen, Section Editor)

Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases

Spondyloarthritis (MA Khan, Section Editor)

Causality of Chlamydiae in Arthritis and Spondyloarthritis: a Plea for Increased Translational Research

Scleroderma (J Varga, Section Editor)

Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits